((4- (4- amidinophenoxy)butanoyl)aspartyl)valine

Subscribe to Selected New Research on ((4-(4-amidinophenoxy)butanoyl)aspartyl)valine

6 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: structure given in first source

Also Known As:

FK 633; FK-633; FK633

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Peptides: 16074

Oligopeptides: 165

Dipeptides: 103

((4-(4-amidinophenoxy)butanoyl)aspartyl)valine: 6

Related Diseases

1.	Hemorrhage 02/15/1996 - "Thus, FK633 is a specific GPIIb/IIIa antagonist with potent anti-thrombotic effect in vivo, but careful dosing study might be necessary to avoid the bleeding complications in the clinic." 08/01/2004 - "CONCLUSIONS: An ultra-short acting glycoprotein IIb/IIIa antagonist, FK633, is effective in preventing both platelet aggregation and thrombocytopenia during CPB, and may be effective for minimizing postoperative bleeding." Get all the results and reference details, order at left...
2.	Thrombocytopenia (Thrombopenia) 08/01/2004 - "CONCLUSIONS: An ultra-short acting glycoprotein IIb/IIIa antagonist, FK633, is effective in preventing both platelet aggregation and thrombocytopenia during CPB, and may be effective for minimizing postoperative bleeding." Get all the results and reference details, order at left...
3.	Thrombosis (Thrombus) 02/01/1998 - "Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model." 03/01/1997 - "Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery." 02/15/1996 - "In dogs, bolus injection of FK633 at 0.1 mg/kg significantly suppressed ex vivo ADP-induced platelet aggregation (>40% inhibition) and thrombus formation at stenosed and injured coronary artery, but did not prolong template bleeding time" 02/01/1998 - "Pretreatment with 0.32 mg/kg i.v. of FK633 significantly prevented occlusive thrombus formation, but aspirin at 10 mg/kg i.v. did not" Get all the results and reference details, order at left...
4.	Hypothermia 01/01/2008 - "However, at hypothermia FK633 and eptifibatide induce platelet activation" 01/01/2008 - "MATERIALS AND METHODS: Control (untreated) and treated (using either FK633 [half-life: 0.52 h], tirofiban [half-life: 1.5-2 h], or eptifibatide [half-life: 1.5 h]) heparinized blood was circulated in an ECC-model at normothermia (37 degrees C) and hypothermia (18 degrees C)" Get all the results and reference details, order at left...
5.	Pathologic Constriction (Stenosis) 02/01/1999 - "The area of intima and media and the area stenosis (1.3+/-0.2 mm2, 41.8+/-7.5% and 1.3+/-0.2 mm2, 33.9+/-6.7% in the FK633 and the control group, respectively) were not different between the groups" Get all the results and reference details, order at left...
7 Diseases and 6 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Glycoproteins (Glycoprotein)
2.	Dihydrotachysterol (AT 10)
3.	Aspirin (Acetylsalicylic Acid)
4.	Adenosine Diphosphate (ADP)
5.	integrin alphavbeta1
6.	eptifibatide (Integrilin)
7.	tirofiban (Aggrastat)
7 Drugs and Important Bio-Agents and 5 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>